Collectively, pharmacological inhibition of SK1 appears to be an effective therapeutic strategy for the treatment of triple negative breast cancer (please see more details in the section SK1 Inhibition as a Therapeutic Tool—Preclinical Evidence). This evidence concerns the gene SPHK1 and triple-negative breast carcinoma.